Entrepreneur-in-Residence, Value-Based Care, Roivant Health at Roivant Sciences

New York, New York, United States

Apply Now

Not SpecifiedCompensation

Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Healthcare, BiotechnologyIndustries

Requirements

Exceptional academic background
Proven track record of successfully founding and growing a tech-enabled healthcare services or technology

Responsibilities

Bring forward, ideate, and refine a concept for a technology-enabled platform or service within the value-based care landscape
Lead early opportunity validation, including unmet need assessment, stakeholder interviews, data analysis, and early go-to-market planning
Build critical partnerships with health plans/payers, provider groups, and other risk-bearing entities to test, refine, and scale your solution
Collaborate closely with Roivant’s operating partners, product leaders, and healthcare experts to develop the business model and execution plan
Lead early hiring and company formation efforts, with a transition toward CEO responsibilities as the company is launched
Drive commercialization strategies and initial revenue generation efforts for new initiatives, focusing on scalable and sustainable growth, particularly through contracting and sales to health plans and other risk-bearing organizations
Provide strategic insights and market intelligence from the value-based care and payer landscape to inform new venture development and existing portfolio company strategies

Skills

Value-Based Care

Healthcare Innovation

Entrepreneurship

Biotech

Drug Development

Health Technology

Roivant Sciences

Develops biopharmaceuticals and RNA therapeutics

About Roivant Sciences

Roivant Sciences develops and delivers medicines and technologies aimed at improving patient health, focusing on drug candidates for genetic disorders and RNA therapeutics. The company operates in the biopharmaceutical market, which involves creating drugs from biological sources. Roivant's unique business model combines in-house development with strategic partnerships, allowing it to build a strong pipeline of drug candidates and utilize advanced technologies to meet medical needs. A key subsidiary, Genevant, specializes in RNA therapeutics, employing proprietary delivery platforms for mRNA, RNAi, and gene editing to treat specific diseases. Roivant generates revenue through drug development, licensing agreements, and partnerships, with the goal of bringing innovative treatments to market efficiently.

New York City, New YorkHeadquarters

2014Year Founded

$1,750.9MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

201-500Employees

Benefits

Remote Work Options

Risks

Integration challenges from Dermavant acquisition may disrupt operations and delay development.

Regulatory hurdles in Pulmovant collaboration with Bayer could impede progress.

Failure of lupus drug brepocitinib may lead to financial losses and investor concerns.

Differentiation

Roivant Sciences focuses on late-stage drug candidates, reducing development time and cost.

The company builds Vants, nimble biotech firms, to enhance drug development efficiency.

Roivant leverages RNA therapeutics, including mRNA and RNAi, for innovative treatments.

Upsides

Roivant's acquisition of Dermavant expands its dermatology portfolio and therapeutic areas.

Strategic partnerships with Bayer and Roche accelerate drug development and market entry.

Increased investment from financial institutions highlights confidence in Roivant's growth potential.

Land your dream remote job 3x faster with AI

Try Jobo Free